Srinivas Guruprasad, Anversa Piero, Frishman William H
Department of Medicine, Montefiore Medical Center, Bronx, New York, NY, USA.
Cardiol Rev. 2009 Jan-Feb;17(1):1-9. doi: 10.1097/CRD.0b013e31817bd7ab.
The regenerative capacity of the myocardium and its blood vessels has now been well demonstrated. The cytokines granulocyte colony-stimulating factor, erythropoietin, and stem cell factor may play a role in helping to stimulate cell regeneration under normal physiologic conditions and in patients with myocardial injury. After an ischemic insult, cytokines are released into the peripheral circulation and signal for the mobilization of stem cells. In experimental cardiac injury models, the addition of cytokines has been shown to improve myocardial function with and without the concurrent use of stem cell therapy. Preliminary studies in humans using cytokine therapy alone for treating myocardial infarction have been disappointing. Future studies in patients with myocardial injury need to examine the use of various combinations of cytokines, with and without the addition of intravascular stem cell infusions or direct stem cell injections.
心肌及其血管的再生能力现已得到充分证实。细胞因子粒细胞集落刺激因子、促红细胞生成素和干细胞因子可能在正常生理条件下以及心肌损伤患者中有助于刺激细胞再生。缺血损伤后,细胞因子释放到外周循环中,并发出动员干细胞的信号。在实验性心脏损伤模型中,已表明添加细胞因子无论是否同时使用干细胞疗法都能改善心肌功能。在人类中单独使用细胞因子疗法治疗心肌梗死的初步研究令人失望。未来针对心肌损伤患者的研究需要考察各种细胞因子组合的使用情况,包括是否添加血管内干细胞输注或直接干细胞注射。